Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma.

Kelderman, S; Heemskerk, B; van Tinteren, H; van den Brom, R; Hospers, G; van den Eertwegh, A; Kapiteijn, E; de Groot, J; Soetekouw, P; Jansen, R; Fiets, E; Furness, A; Renn, A; Krzystanek, M; Szallasi, Z; Lorigan, Paul C; Gore, M; Schumacher, T; Haanen, J; Larkin, J; Blank, C

Affiliation

Netherlands Cancer Institute NKI-AVL, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands

Issue Date

2014-05

Metadata

Show full item record

Abstract

Ipilimumab, a cytotoxic T lymphocyte-associated antigen-4 blocking antibody, has improved overall survival (OS) in metastatic melanoma in phase III trials. However, about 80 % of patients fail to respond, and no predictive markers for benefit from therapy have been identified. We analysed a 'real world' population of patients treated with ipilimumab to identify markers for treatment benefit.

Citation

Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. 2014, 63 (5):449-58 Cancer Immunol Immunother

Journal

Cancer Immunology, Immunotherapy

URI

http://hdl.handle.net/10541/322586

DOI

10.1007/s00262-014-1528-9

PubMed ID

24609989

Type

Article

Language

ISSN

1432-0851

Collections

All Christie Publications